Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)
NCT05116982 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47
Last updated 2022-09-16
Summary
Aluminum is a very abundant element in nature. Humans are exposed to this metal through the environment, diet, and drinking water, as well as through the consumption of certain medications.
Aluminum is not an essential element for human, being able to become neurotoxic when it reaches the brain once ingested at very high doses and, above all, if there is also kidney dysfunction.
Silicon is one of the most abundant elements on the planet and although it is not considered an essential element for humans, some beneficial activities have been documented.
Silicon has been found to be readily available in food and that 41% of ingested silicon is excreted in the urine, with a significant correlation between silicon ingested with food and urinary silicon excretion.
The most bioavailable silicon is that found in the form of silicic acid or orthosilicic acid.
Numerous studies suggest that silicon can reduce the oral absorption of aluminum and / or improve its excretion and, therefore, protect against the adverse effects induced by the ingestion of aluminum.
In a clinical study with healthy individuals as a control group for Alzheimer's disease, the levels of aluminum excretion were analyzed after the continuous ingestion of water enriched in silicon. The results in the first urine of the morning during the first week of ingestion of the enriched water showed that the excretion of aluminum was 136.9 ± 81.4 µmol / nmol creatinine while in the baseline week it was lower, 98.8 ± 64.3 nmol / nmol creatinine. These results indicated that the Al excreted came from Al stored in the body.
The main objective of the study is to evaluate the effect of the consumption of three food supplements formulated with different silicon compounds (monomethylsilanetriol and / or silicic acid) on the urinary excretion of aluminum.
The secondary objectives of the study are to evaluate:
* the bioavailability of the silicon contained in three food supplements formulated with different silicon compounds.
* the effect of the consumption of three food supplements formulated with different silicon compounds on urinary excretion of mercury, nickel, arsenic, cadmium, iron and copper.
* the safety of the consumption of three food supplements formulated with different silicon compounds.
Conditions
- Aluminium Overload
- Biological Availability
Interventions
- DIETARY_SUPPLEMENT
-
ORGONO Living Silica Acacia Gum-MMST Powder
Participants will consume one capsule per day and one bottle per day. Capsule composition: Acacia Gum 336.1 mg/capsule; Monomethylsilanetriol 34.9 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
- DIETARY_SUPPLEMENT
-
ORGONO Living Silica Malto-OSA Powder
Participants will consume one capsule per day and one bottle per day. Capsule composition: Maltodextrin 311.4 mg/capsule; Silicic acid 35.6 mg/capsule; Hydroxypropyl methylcellulose 95 mg/capsule. Bottle composition: water 100 ml. Silicon content per dose: 10.4 mg.
- DIETARY_SUPPLEMENT
-
ORGONO Living Silica Collagen Booster
Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 99.9646 g/100 ml; Silicic acid 23.65 mg/100 ml; Monomethylsilanetriol 11.75 mg/100 ml. Silicon content per dose: 10.4 mg.
- DIETARY_SUPPLEMENT
-
Placebo
Participants will consume one capsule per day and one bottle per day. Capsule composition: Hydroxypropyl methylcellulose 320 mg/capsule. Bottle composition: water 100 ml.
Sponsors & Collaborators
-
Silicium Laboratories S.L.
collaborator UNKNOWN -
San Antonio Technologies S.L.
collaborator UNKNOWN -
Catholic University of Murcia (UCAM)
collaborator UNKNOWN -
Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency
collaborator UNKNOWN -
Fundació Eurecat
lead OTHER
Principal Investigators
-
Josep M Del Bas, PhD · UTNS (Eurecat-Reus)
-
Pilar Zafrilla, PhD · Universidad Católica San Antonio de Murcia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-05-09
- Primary Completion
- 2022-06-12
- Completion
- 2022-06-12
Countries
- Spain
Study Locations
More Related Trials
-
Effectiveness of Aquamin® in Mitigating Halitosis
NCT05058638 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste
NCT02992314 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Natural Enzymes Mouthwash: a Randomised Controlled Trial
NCT05640362 ·Status: COMPLETED ·Phase: NA
-
In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
NCT01405794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Chewing Gum in Hemodialysis Patients
NCT05241587 ·Status: COMPLETED ·Phase: NA
-
Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use
NCT05950529 ·Status: COMPLETED ·Phase: NA
-
Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel.
NCT07235332 ·Status: ENROLLING_BY_INVITATION
-
Clinical Study New Gel for Xerostomia
NCT04184908 ·Status: UNKNOWN ·Phase: PHASE1
-
Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients
NCT06984848 ·Status: RECRUITING ·Phase: NA
-
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
NCT01652001 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy (Preliminary) and Safety of Artificial Salivary Containing Cumin and Ginger Extract in Healthy Volunteer
NCT04997889 ·Status: RECRUITING ·Phase: NA
-
In Vivo Assessment of Silver Biomaterial Nano-Toxicity
NCT01243320 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Plasticizer Exposure and Its Consequences on Health
NCT06512298 ·Status: NOT_YET_RECRUITING
-
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva
NCT01690052 ·Status: COMPLETED ·Phase: NA
-
Lipid Peroxidation in Workers Exposed to Al,Ga,In,As,and Sb in Optoelectronic Industry
NCT00383981 ·Status: COMPLETED
-
Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders
NCT03704168 ·Status: WITHDRAWN ·Phase: NA
-
Contact Allergies to Dental Metal as a Possible Risk Factor for Oral Cancer
NCT00693550 ·Status: COMPLETED
-
Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)
NCT06195137 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Salivary-free Amino Acids Levels (Glycine , Proline , Lysine , and Alanine ) With Caries Activity
NCT06953557 ·Status: NOT_YET_RECRUITING
-
Zinc Supplementation in Cirrhotic Patients
NCT02475928 ·Status: UNKNOWN ·Phase: NA
-
Endocrine Disruptors in Saliva Released From Bruxism Splints.
NCT06088238 ·Status: UNKNOWN
-
A Stimulator of the Salivary Vibration of the Parotid Glands
NCT05129111 ·Status: COMPLETED ·Phase: NA
-
Efficacy of a Dietary Supplement (Aqualief®) in Xerostomic Patients
NCT03612414 ·Status: COMPLETED ·Phase: NA
-
Evaluation of an Electro-stimulator for the Treatment of Xerostomia
NCT00509808 ·Status: COMPLETED ·Phase: PHASE4
-
Day Long Prevention of Oral Malodor With a Palatal Patch (SmellX) Containing A Herbal Formula
NCT01388023 ·Status: COMPLETED ·Phase: PHASE2